Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
28 Août 2024 - 1:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of August 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
Transaction notification
Issued: 27 August 2024, London UK
Statement: Zantac (ranitidine) litigation - Delaware Supreme Court
to review Superior Court's Daubert decision
GSK plc (LSE/NYSE: GSK) welcomes today's decision by the Delaware
Supreme Court that it will review the Delaware Superior Court's
decision allowing the introduction of plaintiffs' expert evidence
at trial. Interlocutory reviews are granted in exceptional
circumstances, and GSK is pleased that the Supreme Court is of the
view that such circumstances are present here.
The scientific consensus remains that there is no consistent or
reliable evidence that ranitidine increases the risk of any cancer.
Since 2019, there are 16 epidemiological studies looking at human
data regarding the use of ranitidine, including outcomes for more
than 1 million patients using ranitidine, supporting this
consensus.
GSK is committed to vigorously defending itself and managing this
litigation in the best interests of the Company and its
shareholders. The Delaware litigation will progress in parallel
with the Delaware Supreme Court review. Alongside review by the
Delaware Supreme Court, the Company will press additional defenses
in the litigation, including failure to provide proof of use and
proof of diagnosis requirements recently ordered by the
Court.
Notes to Editors
* The Daubert standard, established in the U.S. Supreme Court case
Daubert v. Merrell Dow Pharmaceuticals, Inc. 509 US 579 (1993)
provides criteria for evaluating whether expert testimony is
admissible under Federal Rule of Evidence 702. Under Rule 702 and
Daubert, an expert may offer testimony if he or she is qualified by
knowledge, education, training or experience in a given area and
the testimony offered is reliable, relevant and helpful to the
jury. In applying the Daubert standard, the Court acts as a
gatekeeper, ensuring that expert opinions meet certain standards
for reliability and that speculative or unreliable opinions are not
presented to the jury. In Daubert, the Supreme Court
identified four factors to guide assessment of an expert's
methodology: (1) whether the expert's methodology has been tested
or is capable of being tested; (2) whether the theory or technique
used by the expert has been subjected to peer review and
publication; (3) whether there is a known or potential error rate
of the methodology; and (4) whether the technique has been
generally accepted in the relevant scientific community. The
Daubert standard is applicable to expert testimony in all federal
cases. Many states also have adopted standards identical to the
federal Daubert standard.
The term "Daubert Standard" comes from the United States Supreme
Court case: Daubert v Merrell Dow Pharmaceuticals Inc 509 US 579
(1993).
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
GSK enquiries
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Dan Smith
|
+44 (0) 20 8047 5502
|
(London)
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q2 Results for 2024.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: August
28, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (PK) (USOTC:GLAXF)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
GSK (PK) (USOTC:GLAXF)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025